DOI 10.1007/s12185-026-04224-z
Effectiveness and tolerability of switching from 20% subcutaneous immunoglobulin to hyaluronidase-facilitated subcutaneous immunoglobulin 10% in the same patients with secondary hypogammaglobulinemia.
Аннотация
PURPOSE AND
METHODS
The availability of high-concentration 20% subcutaneous immunoglobulin (SCIG 20%) and hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) has recently expanded therapeutic options for immunoglobulin replacement therapy in patients with secondary immunodeficiency (SID). The present study aimed to confirm the effectiveness and tolerability of each SCIG formulation in eight patients with SID switched from SCIG 20% to fSCIG 10% and to inform SCIG selection in clinical practice.
RESULTS
The number of infection events varied among patients and was generally low during each SCIG administration. At the individual patient level, no significant difference was observed in infection rates between SCIG 20% and fSCIG 10%. Local adverse events occurred more frequently with fSCIG 10% than with SCIG 20%. Local adverse events with fSCIG 10% persisted as treatment continued but remained mild.
CONCLUSION
These results suggest that dosing interval preferences, adverse event tolerability, and shared decision-making are important considerations in SCIG selection.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.